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ABSTRACT
Previous studies have linked cancer cell-associated ADAM28 expression with 
tumor progression and metastatic dissemination. However, the role of host-derived 
ADAM28 in cancer dissemination processes remains unclear.
Genetically engineered-mice fully deficient for ADAM28 unexpectedly display 
increased lung colonization by pulmonary, melanoma or breast tumor cells. In 
experimental tumor cell dissemination models, host ADAM28 deficiency is further 
associated with a decreased lung infiltration by CD8+ T lymphocytes. Notably, naive 
ADAM28-deficient mice already display a drastic reduction of CD8+ T cells in spleen 
which is further observed in lungs. Interestingly, ex vivo CD8+ T cell characterization 
revealed that ADAM28-deficiency does not impact proliferation, migration nor 
activation of CD8+ T cells. Our data highlight a functional role of ADAM28 in T cell 
mobilization and point to an unexpected protective role for host ADAM28 against 
metastasis.
INTRODUCTION
ADAM28 (A Disintegrin And Metalloproteinase 
28) is a membrane-bound proteinase (mADAM28) that 
also exists as a shorter secreted form (sADAM28) [1]. 
In humans, ADAM28 is mainly found to be expressed 
by lymphocytes, lymphoid tissues and epithelial cells 
whereas in mice, ADAM28 is expressed by epididymis 
and thymic epithelial cells. Both isoforms exhibit pro-
tumor effects through their proteolytic activities [2, 3, 
4, 5]. Overexpression of ADAM28 by carcinoma cells has 
been described in a wide range of cancers including breast 
cancer, chondrosarcoma [6], head and neck carcinoma 
[7], B-cell acute lymphoblastic leukemia [8], bladder 
carcinoma [9], non-small cell lung carcinoma (NSCLC) 
[10] and prostate cancer [11]. In NSCLC, ADAM28 
expression levels correlate with cell proliferation, tumor 
growth and lymph node metastasis [10]. Yet, ADAM28 has 
been proposed as an effective biomarker for diagnosis and 
monitoring of NSCLC [12]. Several in vivo mouse studies 
demonstrated that specific knockdown of both ADAM28 
forms in tumor cells using siRNA or shRNA delays 
primary tumor growth and lung metastasis of mammary 
MDA-MB-231 xenografts. Moreover, lung metastasis 
induced by an intravenous injection of prostatic PC-9 
or MDA-MB-231 cells was decreased when ADAM28 
expression was inhibited in tumor cells. Altogether, these 
findings strongly suggest that pro-tumor roles should 
be ascribed to ADAM28 produced by tumor cells and 
recommend ADAM28 as a promising therapeutic target.
Metastatic dissemination is not only dependent 
on intrinsic properties of tumor cells since the active 
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participation of the surrounding tumor microenvironment, 
notably composed of endothelial cells, fibroblasts 
and immune cells, has been demonstrated. Hence, the 
adaptive immune system provides an effective response 
against tumors, mainly mediated by CD8+ cytotoxic T 
lymphocytes (CTLs), which induce tumor cell death 
through perforin-Granzyme release or via Fas/FasL 
pathway [13]. CD4+ T cells also play critical roles in anti-
tumor responses as they indirectly stimulate CD8+ T cells 
by secreting pro-inflammatory cytokines that support 
CD8+ T cell activities [14]. In this context, infiltration 
of human lung tumors by CTLs has been significantly 
correlated with an improved outcome of NSCLC patients 
[15–21]. Moreover, predominant roles in restraining tumor 
growth and progression have been assigned to CTLs using 
transgenic mouse models of lung tumors.
In the present study, we demonstrate a strong 
link between host ADAM28 deficiency and tumor cell 
colonization in lungs. To assess ADAM28 implication 
in metastatic processes, we developed a mouse strain 
fully deficient for ADAM28. Surprisingly, ADAM28 
deletion resulted in an increased metastatic colonization 
of lung tissues after intravenous injection of pulmonary 
LLC, melanoma B16K1 or mammary 4T1 cells. This 
induced tumor cell implantation in ADAM28 deficient 
lungs was associated with a strong reduction of CD8+ 
T cell infiltration in lung tissues as compared to wild-
type (WT) animals. Our innovative data pinpoint a new 
protective role of host-derived ADAM28 against tumor 
cell colonization in lungs, specifically by its effects 
on cytotoxic CD8+ T cell mobilization to lungs bearing 
metastatic tumor islets, where CD8+ T cells are supposed 
to exert anti-tumor functions.
RESULTS
Generation and characterization of an ADAM28 
full knockout mouse strain
As illustrated in Figure 1A, a conditional floxed 
allele of the ADAM28 encoding gene was generated 
by flanking exon 2 with loxP sites (targeted allele). 
Intercrossing of mice bearing a floxed ADAM28 allele, 
first with a deleter flippase, then with a deleter-Cre strain 
removed the neomycin selection cassette and the loxP-
flanked exon 2, respectively. Intercrossing of heterozygous 
mice led to a mouse strain fully deficient for ADAM28 
(KO) as well as to corresponding wild-type littermates. 
Amplification of DNA extracted from mouse tail biopsies 
using selective primers flanking the 5’ and 3’ extremities 
of the floxed exon 2 (just before and after both inserted 
loxP sites) showed that ADAM28-deficient mice bear 
a shorter DNA copy (153 base pairs, lanes 3-4) when 
compared to corresponding wild-type mice (623 base 
pairs, lanes 1-2) (Figure 1B), confirming the lack of 
exon 2. Cre-mediated deletion of exon 2 did not affect 
ADAM28 mRNA transcript levels in lungs, as measured 
by semi-quantitative RT-PCR using primers designed to 
amplify the active site domain of ADAM28 (Figure 1C-
1D). However, using primers specifically targeting exon 
2 confirmed the exon 2 removal since no transcripts 
could be amplified in thymus and lungs of ADAM28 KO 
mice (Figure 1E, lanes 4-6; 10-12). ADAM28 deficient 
pups display no apparent defect (Figure 1F), gain weight 
in the same manner as WT littermates over 30 weeks 
(Figure 1G) and are fertile. Moreover, ADAM28 KO and 
corresponding WT mice intercrosses yield similar litter 
size (Figure 1H).
In order to verify whether other members of the 
ADAM family, known to have pro-tumor functions and 
implicated in thymocyte development and maturation, 
were upregulated to compensate ADAM28 deficiency, 
Western Blot analyses measuring ADAM10 and 
ADAM17 levels were performed on thymic protein 
extracts from WT and ADAM28 deficient mice 
(Supplementary Figure 1). No significant difference 
in ADAM 10 and 17 protein levels was observed 
between experimental groups, ruling out compensatory 
mechanisms for ADAM28 deficiency.
ADAM28 deficient mice display increased tumor 
cell colonization in lungs
To evaluate the implication of host-derived 
ADAM28 in metastatic processes, an experimental 
metastasis assay was conducted on ADAM28 deficient and 
corresponding control wild-type mice using intravenously 
injected luciferase-expressing LLC tumor cells. 
Interestingly, an increased LLC-related bioluminescence 
was quantified in lungs of ADAM28 deficient mice 
(p=0.2) (Figure 2A). Quantification of haematoxylin-
eosin-stained histological lung sections confirmed a 
significant increase in tumor density in lungs of ADAM28 
KO mice (KO+LLC) (*p<0.05) (Figure 2B-2C). Kaplan-
Meier survival curves show that survival percentages 
of mice deficient for ADAM28 and injected with LLC 
cells were reduced, suggesting a more rapid metastatic 
pulmonary colonization (Figure 2D). The increased tumor 
cell dissemination to lung parenchyma of ADAM28 KO 
mice was also demonstrated with B16K1 melanoma cells 
(**p<0.01) (Figure 2E-2F). To verify whether the observed 
tumor phenotype was related to genetic background of the 
C57BL/6JRj mouse strain used in previous experiments, 
ADAM28 KO mice were backcrossed with Balb/cJRj 
mice and challenged with intravenous injections of 
mammary 4T1 cells. Again, Balb/cJRj ADAM28 KO 
mice displayed an enhanced tumor density in lungs when 
compared to corresponding WT littermates (*p<0.05) 
(Figure 2G-2H). Importantly, LLC, B16K1 and 4T1 
tumor cells used in this study did not express ADAM28 
mRNA (Supplementary Figure 2A), suggesting that only 
ADAM28 expressed by host non-tumoral tissues impacts 
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Figure 1: Knockdown strategy of the gene encoding ADAM28 in mouse. (A) Targeting strategy to generate ADAM28 floxed 
(targeted allele) and ADAM28 null (KO allele) alleles. Restriction map depicting the wild-type (WT) ADAM28 gene locus (exons 1-6 
(represented by white boxes)). In the targeting vector, the exon 2 has been flanked by loxP sites (grey triangles) and a neomycin selection 
cassette (NEO) flanked by frt sites (black ellipses). A diphteria toxin A (DTA) cassette is inserted at the 5’-site of the targeting vector. 
The grey bars under the restriction maps indicate sizes of BamHI (B) and HindIII (H) digestion–derived restriction fragments detected 
in wild-type and recombinant loci. DNA probes for Southern blot analysis (grey boxes) were designed outside the targeting vector. The 
ADAM28 null allele (KO) is obtained after a first Flp-excision of the NEO cassette followed by a Cre-mediated excision of exon 2. (B) 
DNA genotyping of WT (lanes 1-2) and ADAM28 KO littermates (lanes 3-4). ADAM28 KO mice bear a 153 bp-DNA short copy, while 
WT mice bear a 623-bp DNA copy of the ADAM28 gene. (C) Semi-quantitative RT-PCR measuring ADAM28 transcripts in lungs of 
tumor-free WT (lanes 1-3) and ADAM28 KO (lanes 4-6) mice. 28S ribosomal RNA levels are shown as loading control. (D) Quantification 
of relative ADAM28 mRNA expression in lungs of WT and ADAM28 KO mice. Results are expressed as arbitrary units corresponding 
to the ADAM28/28S ratio. Bars represent SEM (n=3). (E) Semi-quantitative RT-PCR measuring ADAM28 mRNA transcripts in thymus 
and lungs of WT (lanes 1-3; 7-9) and ADAM28 KO (lanes 4-6; 10-12) mice using primers targeting exon 2. (F) Wild-type and ADAM28 
knockout littermates at 8 weeks of age. (G) Weight-gain curves of WT and ADAM28 KO littermates. Bars represent SEM. (H) Number of 
matings and mean litter size ± SEM for each genotype. These values were determined by considering the number of births obtained over 
one year for one couple per genotype.
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Figure 2: ADAM28 deletion in host tissues promotes metastasis to lung tissues. (A) Biophotonic monitoring of lungs of WT 
(n=18) and ADAM28 KO mice (n=22), 21 days after intravenous injection of luciferase- transfected LLC cells. (Mann-Whitney; p=0.2). 
Images shown have been taken in ‘Photon mode’. The right panel shows the quantification of luminescent signals in regions of interest 
(ROI) in lungs. (B) Quantification of tumor density on HE-stained lung sections from WT (n=25) and ADAM28 KO (n=20) mice at day 21 
after intravenous LLC cell injection. (Mann-Whitney; *p< 0.05). Representative data from three independent experiments are shown. (C) 
Representative images of HE-stained lungs from WT and KO mice bearing LLC tumors (black arrows) (scale bar: left panel: 2500 μm). The 
right panel (scale bar: 250 μm) is a zoom of a tumor area present in lungs of each genotype. (D) Kaplan-Meier curves measuring survival of 
WT (n=13) and ADAM28 KO (n=17) mice over 50 days after intravenous LLC cell injection (Mantel-Cox; *p=0.022). (E) Quantification of 
tumor density in HE-stained lung tissue slides of WT (n=20) and ADAM28 KO (n=19) mice at day 28 after B16K1 cell injection. (Mann-
Whitney; **p< 0.01). Representative data from three independent experiments are shown. (F) HE-stained lung sections from WT and KO 
mice bearing B16K1 tumors (arrow) (scale bar: 2500 μm) (G) Quantification of tumor density on HE-stained lung sections from WT (n=11) 
and ADAM28 KO (n=11) mice at day 14 after 4T1 cell injection. (Student’s t test; *p<0.05). Representative data from two independent 
experiments are shown. (H) Representative images of HE-stained lungs from WT and KO mice bearing 4T1 tumors (black arrows) (scale 
bar: 2500 μm).
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tumor cell implantation to lungs. Taken together, these 
results demonstrate that ADAM28 deficiency in the 
pulmonary tumor-microenvironment is linked to increased 
tumor cell colonization in lungs.
ADAM28 deficiency does not impact tumor cell 
proliferation and apoptosis
To evaluate the direct influence of ADAM28 
deficiency on tumor cell behavior in vivo, proliferation 
and apoptosis rates were assessed in tumor foci colonizing 
lung tissues by Ki-67 and caspase 3 immunohistochemical 
staining, respectively. In this purpose, lungs of WT and 
ADAM28 KO mice bearing same sized-tumor islets were 
analyzed. As demonstrated in Supplementary Figure 
2B-2C, the absence of ADAM28 in host tissues did not 
influence cell proliferation or apoptosis rates in tumors.
ADAM28 deletion decreases CD8+ T cell 
recruitment to the spleen and to tumor-bearing 
lungs
As ADAM28 is described to be expressed by thymic 
epithelial cells and as CD8+ T cells are the main effectors 
in tumor immunity, the migration profiles of differentiated 
CD8+ T cells from the thymus to their secondary activation 
sites (spleen and lungs) were investigated. For this, flow 
cytometry analyses were performed on whole spleen and 
lungs derived from C57BL/6JRj WT and ADAM28 deficient 
mice, intravenously injected with LLC tumor cells (21 days 
after LLC cell injection), and from C57BL/6JRj tumor-free 
mice. Interestingly, among CD3+ cells present in splenic 
tissues, reduced CD8+ T cell percentages were observed 
in ADAM28 KO mice, 21 days after LLC cell injection 
(KO+LLC, *p<0.05) (Figure 3A). A significant reduction 
of CD8+ T cell percentages was also noticed in ADAM28 
KO lungs, once tumors were firmly established in the lung 
parenchyma (21 days after intravenous LLC cell injection) 
(**p<0.01) (Figure 3B). Immunofluorescence staining of 
CD8+ T cells infiltrating lungs bearing equally-sized tumors 
confirmed flow cytometry data showing a reduction of CD8+ 
T cell density in ADAM28 deficient lungs (Figure 3C-3D) 
(*p<0.05). Pulmonary infiltration by other T cell subtypes 
such as CD4+/CD3+ T cells, Treg (FoxP3+/CD4+) and B cells 
(B220+/CD3-) was not affected by ADAM28 depletion at 
day 21 post-injection (Figure 3E-3G).
As the increased metastatic burden observed in 
ADAM28 KO mice was corroborated using different cell 
lines (LLC, B16K1 and 4T1) and different mouse strains 
(C57BL/6JRj and Balb/cJRj), we investigated whether 
infiltration of CD8+/CD3+ T cells was also affected in 
C57BL/6JRj mice injected with B16K1 cells or 4T1-
injected Balb/cJRj mice. Hence, spleen and lungs of 
C57BL/6JRj ADAM28 KO mice, injected with B16K1 
cells and bearing well developed tumors, displayed 
significant lower CD8+ T cell percentages as compared 
to corresponding WT littermates (day 35 post-injection, 
*p<0.05; **p<0.01) (Figure 3H-3I). Decreased CD8+ 
T cell numbers were also found in spleen of ADAM28 
knockout mice after intravenous 4T1 cell injection (Figure 
3J) (*p<0.05). Moreover, a clear reduction of CD8+ T cell 
counts could be noticed in ADAM28 deficient lungs once 
4T1 tumors were well established in lung tissues (14 days 
after 4T1 tumor cell injection) (***p<0.001) (Figure 3K).
Remarkably, CD8+/CD3+ T cell percentages were also 
significantly lower in the spleen of tumor-free ADAM28 
KO mice when compared to corresponding WT littermates, 
regardless mouse strain (C57BL/6JRj or Balb/cJRj) (Figure 
4A, 4C) (Balb/cJRj: **p<0.01; C57BL/6JRj: ***p<0.001). 
No statistically significant difference regarding CD8+ 
T cell populations could however be noticed in lungs of 
tumor-free animals (Figure 4B, 4D). Lower percentages of 
CD8+ T cells in spleen and lung tissues were not caused by 
increased apoptosis of CD8+ T cells, since similar apoptosis 
rates were observed among CD8+ T cell populations present 
in spleen of tumor-free mice (Supplementary Figure 3).
Taken together, our data show that the observed 
loss in CD8+ T cell numbers is correlated with ADAM28 
deficiency but is not dependent on the mouse strain 
(C57BL/6JRj or Balb/cJRj) or the tumor cell line used 
(LLC, B16K1 or 4T1) suggesting a conserved mechanism 
among different experimental models.
ADAM28 deficiency does not alter thymus 
development
No difference of thymocyte differentiation stages 
(double-negative CD4-/CD8- (DN1-4); double-positive 
CD4+/CD8+ (DP) (Supplementary Figure 4) or mature 
single positive cells (CD4+/CD8-/B220- and CD8+/CD4-/
B220-) (Figure 4E, Supplementary Figure 4) could be 
highlighted in thymus of 8 week-old tumor-free WT 
and ADAM28 KO mice. The histological organization 
of thymus is similar between both experimental groups 
as demonstrated on thymic tissue slides where cortex 
(C) and medulla (M) distribution is comparable (Figure 
4F). Thymus weight was also not affected by ADAM28 
deficiency (Figure 4G).
Altogether, these results demonstrate that ADAM28 
KO mice display reduced CD8+ T cell percentages in 
spleen that are not linked to an impaired upstream T cell 
maturation in thymic tissues. Hence, the downstream 
reduced infiltration of CD8+ T cells in tumor-bearing 
ADAM28 KO lungs and the putative consequent reduction 
of CD8-related anti-tumor activity seem to promote 
colonization of tumor cells in pulmonary tissues.
ADAM28 deficiency does not impair CD8+ T cell 
activity, proliferation and migration
Proliferation of CD8+ T cells is correlated with 
their activation status. Hence, an altered ability to respond 
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Figure 3: ADAM28 deficiency affects CD8+ T cell mobilization to splenic and pulmonary tissues in tumor-bearing 
mice. (A-B) Percentages of CD8+/CD3+ T cell populations were evaluated in spleen (WT=11, KO=13) and lung tissues (WT=18, KO=21) 
from WT and ADAM28 KO mice 21 days following intravenous LLC cell injection (Student’s t test; Mann-Whitney; spleen: *p <0.05; 
lung: **p <0.01). (C) Representative images of CD8+ T cells stained with anti-CD8 antibody (green) present in lungs bearing equally- sized 
tumors from WT and ADAM28 KO mice. Nuclei were stained with DAPI (blue). Scale bar: 250 μm. (D) Density of CD8 staining was 
measured and reported to total lung area of WT (n = 11) and ADAM28 KO (n = 15) mice (Mann-Whitney; *p <0.05). (E) Evaluation of 
CD4+/CD3+ T cell population percentages by flow cytometry in lungs of WT (n=23) and ADAM28 KO (n=27) mice 21 days following 
intravenous LLC cell injection. (F) Evaluation of Treg (FoxP3+/CD4+) percentages in lungs of WT (n=12) and ADAM28 KO (n=15) mice 
at day 21 post-injection of LLC cells. (G) Percentages of B cells (B220+/CD3-) infiltrated within lungs of WT (n=10) and KO (n=14) mice 
21 days after LLC cell injection. (H-I) Percentages of CD8+ T cells evaluated by flow cytometry on spleen and lungs from WT and KO 
(n = 8) at day 35 after B16K1 cell injection (spleen: Student’s t test; *p < 0.05) (lung: Mann-Whitney; **p < 0.01). (J-K) Flow cytometry 
analysis performed on spleen and lungs from BALB/cJRj WT (n=11) and ADAM28 KO (n=11) mice 14 days following intravenous 4T1 
cell injection. (Student’s t test; spleen: *p < 0.05; lung: ***p < 0.001).
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to activating stimuli could explain lower numbers of 
infiltrating CD8+ T cells observed in spleen and tumor-
bearing lungs of ADAM28 deficient mice. To investigate 
whether the activity profile of CD8+ T cells was impaired 
by ADAM28 deficiency, expression levels of cytokines 
involved in regulating CD8+ T cell responses were 
quantified on whole lung protein extracts from ADAM28 
deficient and corresponding WT mice bearing equally-
sized metastatic foci in lungs. No difference was observed 
for KC and CXCL10 between experimental groups (Figure 
5A-5B). Levels of IL-12, which directly induce CD8+ T cell 
activation, expansion and proliferation were not altered by 
ADAM28 deletion indicating that the ADAM28 deficient 
microenvironment has no effect on the release of soluble 
factors known to regulate CD8+ T cell responses (Figure 5C).
Interestingly, antigens specific to CD8+ T cell 
activation such as Granzyme B (GrzB) or CXCR3 were 
significantly higher in lungs of ADAM28 KO mice 
(**p<0.01) (Figure 5D-5E), 21 days after intravenous LLC 
cell injection. These increased Granzyme B and CXCR3 
levels observed in ADAM28 deficient lungs can thus be 
associated with the increased lung tumor density. Moreover, 
CXCR3 levels expressed on CD8+ T cells isolated from 
tumor-free WT and ADAM28 KO mice and stimulated ex-
vivo with IL-2 and IL-7 were similar between both groups 
(Supplementary Figure 5A). Levels of IFN-γ, which plays 
a critical role in control of CD8+ T cell expansion, were 
similar between experimental groups (Figure 5F). These 
results illustrate that CD8+ T cells infiltrating tumor-bearing 
lungs are well activated even if ADAM28 is lacking.
In addition, basal proliferation rates were similar 
among CD8+ T cells isolated from naive WT and 
ADAM28 KO spleens. Stimulation of CD8+ T cells with 
media conditioned (CM) either from LLC, 4T1 or B16K1 
tumor cells or from wild-type or from ADAM28 deficient 
CD8+ T cells induced their proliferation, regardless of 
ADAM28 production (Figure 5G). Migration of CD8+ 
T cells purified from spleens of ADAM28 KO or WT 
mice was assessed by modified Boyden Chamber assays 
using CXCL10 at different concentrations (Figure 5H, 
Supplementary Figure 5B), CM from tumor cells or 
CM from CD8+ T cells used as chemoattractants (Figure 
5H). Similar profiles of migration have been observed 
between ADAM28 KO and WT CD8+ T cells, regardless 
the chemoattractants used (Figure 5H). Cytotoxic effects 
of ex vivo-isolated CD8+ T cells were also assessed and 
no difference of death or apoptosis rates of LLC cells 
was observed (Supplementary Figure 5C). These data 
demonstrate that CD8+ T cells isolated from ADAM28 KO 
mice display similar proliferation, migration and cytotoxic 
abilities as their WT counterparts. Altogether, these results 
demonstrate that cytokines involved in activation and 
stimulation of CD8+ T cells are commonly produced in an 
ADAM28-depleted tumor-microenvironment.
DISCUSSION
Previous reports, focusing on cancer cell-derived 
ADAM28, have demonstrated that ADAM28 promotes 
cancer development and progression [22, 23]. In the 
Figure 4: ADAM28 deficiency reduces CD8+ T cell mobilization to splenic and pulmonary tissues in tumor-free mice. 
(A-B) CD8+/CD3+ T cell percentages assessed in spleen (n=16) and lungs (WT=9, KO=10) of tumor-free C57BL/6JRj WT and ADAM28 
KO mice (Student’s t test; ***p < 0.001). (C-D) Flow cytometry analyses were performed to evaluate CD8+/CD3+ cell populations present 
in spleen (WT=6, KO=5) and lungs (WT=5, KO=5) of tumor-free BALB/cJRj WT and ADAM28 KO mice (Mann-Whitney; **p <0.01). 
(E) Percentages of CD8+ T cells (CD8+/CD4- B220-) evaluated by flow cytometry in thymus of tumor-free WT (n=11) and ADAM28 KO 
(n=11) mice (Student’s t test; p>0.05). (F) Representative HE-stained sections of thymus derived from WT and ADAM28 KO mice. Cortex 
(C) and medulla (M). Scale bar: 500 μm. (G) Thymus weight of 6 week-old WT (n=5) and ADAM28 KO (n= 5) mice (Student’s t test).
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present study, the influence of total ADAM28 depletion 
in mouse tissues was evaluated on physiological and 
metastatic processes. For the first time, we demonstrate 
a protective role of stromal cell-derived ADAM28 
against colonization of tumor cells to lung tissues. This 
exaggerated cancer cell dissemination in ADAM28 
deficient animals is associated with a defect in CD8+ T 
cell trafficking to tumor-bearing organs. These findings 
are supported by robust experimental data: 1) an increased 
metastatic burden observed in lungs of ADAM28 KO 
mice, without regard to cancer cell type (pulmonary 
LLC, mammary 4T1, melanoma B16K1) or mouse 
strain (C57BL/6JRj and Balb/cJRj) used in experimental 
settings, 2) decreased CD8+ T lymphocyte counts in spleen 
as well as in lung tissues bearing well-developed tumors 
of ADAM28 KO animals, 3) the impaired CD8+ T cell 
recruitment already evident in the spleen of tumor-free 
ADAM28 deficient animals.
Interestingly, tumor cells themselves are not affected 
by the depletion of host-derived ADAM28 since their 
proliferation and apoptosis rates were found to be similar 
in lungs of ADAM28 KO and WT animals.
T lymphocytes are the main effectors of anti-
tumor immune responses and their abundance in tumors 
represents a precious prognostic factor for various cancers 
[24, 25, 26]. Hence depletion or inhibition of CD8+ T cells 
in experimental mouse models negatively impacts tumor 
progression outcomes [27, 28].
Development and maturation of T-cells is a 
complex multistep process, where bone marrow-derived 
T cell progenitors, reaching the thymus, undergo various 
maturation stages. ADAM28 has been shown to be 
expressed in both fetal and adult thymic epithelial cells, 
and its deficiency could thus lead to impaired thymus 
development. In this work, complete depletion of 
ADAM28 did not modify morphological development or 
functionality of the thymus and no defect of lymphocyte 
maturation processes was found. ADAM10 and 
ADAM17 levels were measured to corroborate whether 
a compensatory mechanism was implemented in animals 
lacking ADAM28, which could explain that lymphocyte 
maturation is not affected in our model. Indeed, 
ADAM10 and ADAM17 seem to be key molecules for 
the thymus development since their in vivo deficiency 
Figure 5: Functional features of ADAM28 deficient CD8+ T cells are not impaired. (A-C) Production of KC (A), CXCL10 
(B) and IL-12 (C) was assessed by ELISA on lung protein extracts from WT (n=11) and ADAM28 KO (n=16) mice bearing equally-sized 
tumors (Student’s t test; Mann-Whitney; p>0.05). (D-F). Quantification of Granzyme B (GrzB) (D), CXCR3 (E) and IFN-γ (F) expression 
on CD8+ T cells by flow cytometry in total lung extracts of WT (n=6) and ADAM28 KO (n=8) mice after intravenous LLC cell injection 
(Day 21) (Student’s t test; **p < 0.01). (G) Proliferation assay performed on ADAM28 KO (n=6) and WT (n=6) CD8+ T cells stimulated by 
CM from tumor cells (LLC, 4T1, B16K1) or by CM from CD8+ T cells (Mann-Whitney). (H) Migration assay on CD8+ T cells isolated from 
WT (n=4) and ADAM28 KO (n=4) mice. Chemoattractants used in the lower chamber of the Boyden Chamber were either CXCL10, CM 
from tumor cells (LLC, 4T1, B16K1) or CM from CD8+ T cells previously isolated from WT or ADAM28 deficient mice (Mann-Whitney). 
All results were normalized to the migration of WT CD8+ T cells (without stimulation) considered as baseline migration and expressed as 
fold increase from baseline.
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has been correlated to impaired thymocyte expansion 
and maturation. Our results demonstrate that ADAM10 
and ADAM17 expressions were comparable between 
ADAM28 KO and WT samples, and further suggest that 
ADAM28 is not essential for T cell maturation in thymus.
ADAM28 could contribute to leukocyte 
transmigration by binding α4β1 and α4β7 integrins [29-31] 
and is overexpressed in lymphoblastic leukemia [32]. In 
addition, a recent study showed that ADAM28 promotes 
MZ B-cell generation by Notch2 cleavage [33]. In the 
present study, the distribution of lymphocytic population 
subtypes was evaluated within different organs implicated 
in T cell trafficking. While significant lower counts 
of CD8+ T cells were detected in spleen of ADAM28 
KO mice, no difference of B, CD4+ T and Treg cell 
populations was found. Accordingly, we hypothesize that 
the observed decreased CD8+ T cell population in spleen 
impacts the proportion of CD8+ T cells infiltrating tumor-
bearing lungs. To verify whether tumor density might 
have an influence on CD8+ T lymphocyte infiltration, 
CD8+ T cell pulmonary infiltration was compared between 
ADAM28 deficient and WT mice by specific CD8-
immunofluorescence staining on equally-sized tumors 
and was also found to be decreased in lungs of ADAM28 
KO mice.
Production of KC, CXCL10 and IL-12 cytokines, 
involved in CD8+ T cell infiltration and CD8+ T cell 
activity regulation [34], was explored within tumors but 
no difference of cytokine production was found between 
experimental groups. By various ex vivo assays, we 
demonstrated that intrinsic CD8+ T cell proliferation, 
which is closely linked to their activation status, as 
well as their migration abilities were not impaired in 
ADAM28 deficient animals. Moreover, an ex vivo short 
term cytotoxic assay could demonstrate that CD8+ T cells 
isolated from ADAM28 KO mice are able to efficiently 
kill tumor cells. Higher percentages of Granzyme B 
and CXCR3 were identified on ADAM28 KO CD8+ T 
cells isolated from tumor-bearing lungs, which can be 
correlated to the increased tumor density in ADAM28 KO 
lungs used for this assay. These results demonstrate that 
CD8+ T cells originating from ADAM28-deficient mice 
can be effectively activated in vivo.
ADAM and other matrix proteinases have been 
largely recommended in the literature as promising 
therapeutic targets to counteract cancer progression and 
metastasis spread. However, one has to be careful since 
these promising targets might display dual roles according 
to their expression pattern. Notably, it was previously 
reported that MMP12 increases tumor invasiveness only 
when expressed by tumor cells whereas its expression by 
macrophages can be associated with a better prognosis 
[35]. Moreover, in an experimental breast cancer mouse 
model, an enhanced tumor progression is correlated 
with ADAM12 overexpression by tumor cells that is not 
described when ADAM12 is expressed by stromal cells. 
On the other hand, ADAM12 deficiency in immortalized 
tumor cells isolated from PyMT mice suppresses breast 
tumor progression although no difference in tumor 
growth is observed between ADAM12 null mice and 
wild type littermates [36]. ADAMTS1 (ADAM with 
ThromboSpondin motifs 1), first suggested as an 
interesting therapeutic target in breast cancer management 
[37], has been defined several years later as playing a 
suppressive role in tumor development and was thus 
rather proposed as facilitating apoptotic and anti-tumor 
effects of adjuvant factors used in cancer treatment 
[38]. These contradictory roles seem to be depending on 
molecular properties of ADAM(TS) proteinases. Indeed, 
a study showed that ADAMTS1 impacts angiogenic 
signaling events through two distinct mechanisms. First, 
carboxyl-terminal domain of ADAMTS1 binds to VEGF 
and reduces VEGFR2 phosphorylation affecting the 
angiogenic pathway [39, 40]. Second, catalytic activity of 
ADAMTS1 is required to exert its proangiogenic effects 
as a single mutation in the metalloproteinase domain is 
associated with antiangiogenic/antitumor activities in vivo 
[40, 41]. ADAM23, a non-proteolytic ADAM, is reported 
to exert anti-tumoral effects through its disintegrin domain 
as it specifically interacts with αVβ3 integrin. In MDA-
MB435 cells, it was demonstrated that downregulation of 
ADAM23 enhanced αVβ3 integrin activation leading to an 
increased adhesion and migration of these cells to classic 
integrin ligands. In addition, ADAM23 knockdown was 
associated with an enhanced pulmonary tumor cell arrest 
in immunodeficient mice [42].
Altogether, these studies highlight the relevance 
of both the metalloproteinase and the disintegrin 
domains of ADAM and ADAMTS proteinases. Since 
ADAM28 exhibits proteolytic activities, it could be 
interesting to further investigate these functions through 
the identification of new specific substrates. Indeed, the 
known substrates of ADAM28 are common with other 
ADAMs due to the highly conserved structure. For 
example, IGFBP-3 (Insulin-like growth factor binding 
protein-3) is also cleaved by ADAM12 and vWF (von 
Willebrand Factor) is also processed by ADAMTS13. In 
addition, the disintegrin domain could also be involved 
in important mechanisms as ADAM28 binds different 
integrins, namely α4β1, α4β7 and α9β1.
These examples underline the ambivalence 
concerning the role of metalloproteinases in processes 
leading to tumor development and increase the complexity 
of considering ADAMs as therapeutic targets.
Altogether, our results highlight the crucial 
importance of ADAM28 expressed by the stromal 
compartment in the control of cancer dissemination 
and demonstrate that ADAM28 deficiency decreases 
CD8+ T cell numbers. These findings strongly advocate 
considering ADAM28 as an anti-target protease and raise 
the question whether ADAM28 expression should be used 
as a prognostic factor for cancer patients.
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MATERIALS AND METHODS
Cell culture
Luciferase-expressing mouse Lewis Lung 
Carcinoma (LLC) and mouse 4T1 breast cancer cells were 
purchased from Caliper Life Sciences (Hertogenbosch, 
Netherlands) and American Type Culture Collection 
(Molsheim, France), respectively. Murine melanoma 
B16K1 cells were used as previously described [43]. Cells 
were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM, Gibco, Thermo Fisher Scientific, Merelbeke, 
Belgium) supplemented with 10% fetal bovine serum 
(FBS), penicillin-streptomycin (100 U/ml–100 μg/ml) 
and L-glutamine (2 mmol/l) and maintained at 37°C 
under 5% CO2 atmosphere and 95% humidity. Cells 
were authenticated by Leibniz-Institute DSMZ GmbH. 
Experiments were performed until maximum 10 cell 
passages after authentication. Conditioned media were 
obtained as described previously [44]. Briefly, cells 
were starved with serum-free DMEM and after 1 hour 
the medium was replaced with fresh serum-free DMEM. 
The conditioned medium was collected after 48 hours, 
centrifuged at 1200 rpm for 10 minutes and aliquots were 
stored at -80°C until use.
Animals
Animals were housed in the animal facility of the 
University of Liege (Belgium) with respect to the Animal 
Ethical Committee rules. All animal experiments were 
approved under the references #1376, #1597, #1945 by the 
Animal Ethical Committee of the University of Liege in 
accordance with the institution guidelines for animal care.
Generation of conditional ADAM28 knockout 
mice using the Cre-Lox recombination 
technology
To design a conditional knockout construct for 
ADAM28, mouse BAC DNA was purchased from 
Source Bioscience Lifescience and transfected into Rec+ 
bacteria (SW102). The targeting vector was designed 
by inserting loxP sites into introns around the exon 2, 
which will be removed after recombination by a deleter-
Cre recombinase, leading to a reading frame shift and, 
consequently, to the appearance of an early stop codon in 
the exon 3 and an incomplete shorter protein.
Briefly, 5’ and 3’ annealing arms of the ADAM28 
gene were introduced respectively before and after the 
loxP site and the frt-flanked neomycin selection cassette 
already present in the pL451-vector (Molecular Medicine 
Department, Max Planck Institute of Biochemistry, 
Munich, Germany) using EcoRV, ClaI, BamHI, and NotI 
restriction enzymes. The distal LoxP site and the exon 
2 were then inserted by PCR in the pL451-vector using 
EcoRV and EcoRI enzymes. Correct insertion of all 
fragments was verified by DNA sequencing and enzymatic 
digestion. To ensure maximal accurate homologous 
recombination and avoid random genomic integration of 
the targeting construct, a diphtheria toxin A (DTA) cassette 
was inserted at the 5’-site of the targeting construct. The 
5’ and 3’ arms corresponding to ADAM28 sequences in 
the pL451 plasmid were then used for recombination 
with corresponding sequences on BAC DNA. The final 
targeting construct was retrieved into pBluescript SK 
vector (Stratagene, San Diego, California) using the 
flanking homology arms on 5’ and 3’. The linearized 
targeting vector was then electroporated into mouse R1 
embryonic stem cells, which were previously cultured 
on a feeder layer of ɣ-irradiated embryonic fibroblast 
cells [45]. After 24 hours without selection, transfected 
cells were selected with geneticin (G418, InvivoGen, 
San Diego, California). After 10 days, surviving clones 
were subcultured, then half of each colony was frozen 
while DNA was extracted from the other half to check 
for correct homologous recombination by Southern Blot 
analysis using external probes. For this, each colony was 
screened by performing BamHI or HindIII enzymatic 
digestions, yielding respectively 5kb and 7kb bands in 
targeted alleles (Figure 1A). At least 5 mutant stem cell 
clones were injected into C57BL/6 blastocysts, which 
were further transplanted into foster mice to generate 
germline chimeras. Chimeric mice were mated with 
C57BL/6 females to test for germline transmission. 
Chimeras derived from 4 different clones gave germline 
transmission. Chimeric mice were then first crossed 
with transgenic C57BL/6 mice carrying a deleter-flp 
recombinase (Thierry Van Reeth unpublished, #012930 
The Jackson Laboratory, Maine, USA) to remove the 
neomycin selection cassette and further intercrossed with 
C57BL/6 mice containing a deleter-Cre recombinase 
(KO allele) [46] (#006054, The Jackson Laboratory). 
To obtain homozygous mice fully deficient for the 
ADAM28 gene, heterozygous mice were intercrossed and 
tail biopsies were assayed for DNA expression by PCR 
analysis to identify wild-type, heterozygous or ADAM28 
knockout mice. Chimeric mice were backcrossed at least 
10 times with C57BL/6JRj or Balb/cJRj mice prior to 
experimental procedures. Wild-type control mice used in 
each experiment are always littermates of corresponding 
ADAM28 knockout animals.
Genotyping
Mouse genotyping was performed using PCR 
amplification of genomic DNA extracted from tail 
biopsies (NucleoSpin Tissue Kit, Macherey-Nagel, 
Hoerdt, France). PCR reactions were performed with 
a Taq Polymerase Kit (Takara Taq, Clontech, Saint-
Germain-en-Laye, France) using primers that were 
designed just before and after the targeting construct: 
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(F) 5’-GGAGAACTGGATTCTGCCAA-3’, and (R) 
5’-TAGTTTCAGACGTGAGTGATCG-3’. PCR products 
were resolved on agarose gels.
Experimental in vivo mouse models of metastatic 
dissemination
LLC, B16K1 and 4T1 cells (1x105) were suspended 
in 100 μl of serum-free DMEM and intravenously (IV) 
injected in the lateral tail vein of ADAM28 KO and WT 
mice (C57BL/6JRj or Balb/cJRj). Lung metastasis was 
monitored by measuring bioluminescence of LLC cells up 
to 21 days after tumor cell injection, using in vivo Imaging 
System Xenogen IVIS 200® (Caliper Life Sciences) as 
described previously [47]. Mice injected with B16K1 and 
4T1 cells, not transfected with the luciferase gene, were 
sacrificed 28 days and 14 days respectively after tumor 
cell injection. In another experimental setting, to accurately 
compare LLC lung tumors induced in ADAM28 KO and 
WT mice, metastatic dissemination was monitored in all 
mice every second day until a bioluminescent signal of 
1.5x106 relative to LLC tumor development was reached in 
Regions of Interest (ROI) determined around lung tissues. 
Tumor growth and physical well-being were monitored 
up to 50 days after tumor cell injection. Animals were 
euthanized by cervical dislocation at 1.5x106 bioluminescent 
signal. At day 50, surviving mice were sacrificed. Kaplan-
Meier tumor survival curves were established and P values 
were calculated with log-rank (Mantel-Cox) test.
Flow cytometry
To evaluate T lymphocyte populations in WT and 
KO tissues, spleen, thymus and lungs were harvested 
and fibrotic tissues were digested in collagenase C (1mg/
ml; Gibco) prior to red blood cell lysis (Red Blood Cell 
Lysis Buffer, Sigma Aldrich, Saint-Louis, Missouri). 
Recovered cells were washed and filtered through a 41 
μm nylon net filter (Merck). Cells were then washed, 
stained with fluorochrome-conjugated surface antibodies 
during 30 minutes, fixed and permeabilized using 
Cytofix/Cytoperm (BD Biosciences, Erembodegem, 
Belgium) before intracellular antigen staining. For 
cytokine staining, cells (106 cells/100μl) were stimulated 
for 4 hours (Leukocyte Activation Cocktail, with BD 
GolgiPlug, BD Pharmingen, Erembodegem, Belgium) 
prior staining with fluorochrome-conjugated antibodies. 
Following antibodies were used for flow cytometry 
analysis: CD45-V450 (30-F11), CD3-APC CY7 (17A2), 
CD8-PE (53-6.7), CD4-PERCP CY 5.5 (RM4-5), CD8a-
BB515 (53-6.7), CD45R-APC-eFluor506 (B220) (RA3-
6B2), CD183-APC (CXCR3-173), IFN-γ-PE CY7 (XMG 
1.2), TCR-β-APC (H57-597), CD44-APC CY7 (IM7), 
CD45R-BV510 (B220) (RA3-6B2), CD25-BV421 (7D4) 
(BD Biosciences), FoxP3-PE (FJK-16s), Granzyme 
B-PE (NGZB), CD3-eFluor506 (17A2), CD45R-APC-
eFluor780 (B220) (RA3-6B2) (eBioscience, Thermo 
Fisher Scientific). Data were acquired on FACS CANTO 
II flow cytometer (BD Biosciences) and analyzed using 
BD FACSDiva software (BD Biosciences).
Tissue preparation
Histologic sections of paraffin-embedded lung and 
thymus tissues (5 μm) were stained with hematoxylin and 
eosin (HE) and imaged using the digital slide scanner 
NanoZoomer 2.0-HT system (0.46 μm/pixel (20X) 
scanning resolution) (Hamamatsu Photonics, Hamamatsu 
City, Japan). Metastatic dissemination to lungs was 
evaluated on five HE-stained sections (separated each 
other by 50 μm) per mouse lung by measuring tumor 
area in lungs and reporting it to the total area of lung 
tissue analyzed. Quantification of lung tumor area was 
performed as described previously [48].
Immunofluorescence staining
Frozen lung sections (6 μm) were fixed in acetone 
at -20°C and in methanol 80% at 4°C before incubation 
with a primary rat anti-mouse CD8a antibody (BD 
Pharmingen). After washing, slides were incubated with 
goat anti-rat Alexa Fluor 488-conjugated secondary 
antibody (Invitrogen, Carlsbad, California) and 
mounted with DAPI Fluoromount G (SouthernBiotech, 
Birmingham, USA). Images were taken with the digital 
slide scanner NanoZoomer 2.0-HT system and LX2000 
source (0.46 μm/pixel (20X) scanning resolution).
Interleukin quantification by ELISA
For specific dosages of IL-12, IL-8 (KC), IL-
10, CXCL10, DuoSet ELISA Development kits (R&D 
Systems, Minneapolis, Minnesota) were used following 
the manufacturer’s instructions.
CD8+ T cell isolation and expansion
CD8+ T cells were isolated from spleens of 8 week-
old ADAM28 KO or WT mice as described previously 
[49]. Briefly, after lysis of red blood cells, cells were 
filtered through a 40 μm-cell strainer. CD8+ T cells were 
isolated using CD8a (Ly-2) MACS microbeads (Miltenyi 
Biotec, Bergisch Gladbach, Germany) according to the 
manufacturer’s instructions. Isolated CD8+ T cells were 
then plated into 6-well plates previously coated with 0.5 
μg/ml anti-CD3 and 5 μg/ml anti-CD28 antibodies. After 
24 hours, recombinant mouse IL-7 (0.5 ng/ml) and IL-2 
(0.2 ng/ml) (R&D Systems) were added to each well. After 
4 days of culture, cells were harvested for further analyses. 
Conditioned medium was obtained as described above. 
For this, CD8+ T cells were cultured with serum-free 
RPMI for 48 hours. Conditioned medium was centrifuged 
and aliquots were stored at -80°C until use.
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Proliferation assay
Proliferation assay was performed using a 
CyQUANT cell proliferation assay kit (Invitrogen). 
Briefly, 4x103 CD8+ T cells were seeded in each 
well of a 96-well plate and cultured either in RPMI 
medium supplemented with 2% FBS, in RPMI medium 
supplemented with medium conditioned by LLC, B16K1 
or 4T1 tumor cells or in medium conditioned by CD8+ 
T cells previously isolated from ADAM28 KO or WT 
spleens. Culturing cells in serum-free RPMI medium 
assessed basal proliferation of CD8+ T cells. A cell-lysis 
buffer containing a green dye was added in each well 
and fluorescence intensity, reflecting cell proliferation, 
was measured using a SpectraMax I3 microplate reader 
(Molecular Devices, Sunnyvale, California).
Ex vivo migration assay
Activated CD8+ T cells (2x105 cells/200 μl) were 
suspended in RPMI supplemented with 0.1% BSA and 
placed in the upper chamber of a 6.5mm transwell insert 
displaying a 5 μm-pore size membrane (Corning, Corning, 
New-York). Conditioned medium recovered from tumor 
cells (LLC, B16K1, 4T1 cells) or from CD8+ T cells 
isolated from KO and WT spleens was added in the lower 
chamber. CXCL10 (100 nM, R&D Systems) present in 
the lower chamber of the Boyden Chamber was used as 
a positive control and migration of CD8+ T cells without 
chemoattractant was determined using serum-free RPMI 
medium. After 3 hours of incubation, CD8+ T cells, which 
migrated through the filter, were harvested and stained with 
anti-CD8a-PE antibody. CD8+ T cells were enumerated 
in each experimental condition during 1 minute by FACS 
CANTO II flow cytometer (BD Biosciences). Data were 
analyzed using BD FACSDiva software (BD Biosciences).
RNA Extraction and Reverse Transcription–
Polymerase Chain Reaction (RT-PCR)
Total RNAs were extracted from lungs using 
RNeasy Mini kit (Qiagen, Hilden, Germany) according 
to the manufacturer’s protocol. RT-PCR was performed 
on 10 ng of total RNA using GeneAmp Thermostable 
rTth Reverse Transcriptase RNA PCR Kit (Roche Life 
Science, Indianapolis, Indiana). The following primers 
targeting respectively ADAM28 exon 11 and exon 2 
were used: (F) 5’-CTACTTGAGCTGCAAGTGTCC-3’, 
(R) 5’-CAGGTCCTTGCATCACAGCAT-3’, (F) 
5’-GTAAAAGAGAGACCCAAGAGCCAG-3’ and (R) 
5’-GTAGTCCTTGACAGGTGCTGATG-3’. RT-PCR 
products were resolved on 10% acrylamide gels and 
analyzed with a fluorescence imager (LAS-4000; Fujifilm, 
Minato-ku, Tokyo) after Gel Star staining (Lonza, Bâle, 
Switzerland). Gene expression levels were measured as 
the ratio between expression values of the gene of interest 
and internal 28S rRNA.
Statistical analysis
Reported data are either reported in a scatter plot 
where mean values are presented as a horizontal middle 
line and the SEM by upper and lower horizontal lines or 
as bar graphs were bars represent mean values and error 
bars represent SEM.
Statistically significant values were assessed using 
appropriate tests (Mann-Whitney or t-student tests; 
GraphPad Prism 5). *p<0.05, **p<0.01, ***p<0.001.
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